Publications by authors named "Mark Creighton-Gutteridge"

Claim this Profile
B
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses .
Rocio Montes de Oca, Alireza S Alavi, Nick Vitali, Sabyasachi Bhattacharya, Christina Blackwell, Mark Creighton-Gutteridge

Mol Cancer Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergystic induction of HIF-1alpha transcriptional activity by hypoxia and lipopolysaccharide in macrophages.
Zenghui Mi, Annamaria Rapisarda, Lynn Taylor, Alan Brooks, Mark Creighton-Gutteridge

Cell Cycle· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.
Mark Creighton-Gutteridge, John H Cardellina, Andrew G Stephen, Annamaria Rapisarda, Badarch Uranchimeg

Clin Cancer Res· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel iron chelator that does not induce HIF-1 activity.
Mark Creighton-Gutteridge, Rex M Tyrrell

Free Radic Biol Med· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis